CN114126643A - 包含溶菌酶的广谱抗菌药物制剂及其使用方法 - Google Patents
包含溶菌酶的广谱抗菌药物制剂及其使用方法 Download PDFInfo
- Publication number
- CN114126643A CN114126643A CN202080048142.9A CN202080048142A CN114126643A CN 114126643 A CN114126643 A CN 114126643A CN 202080048142 A CN202080048142 A CN 202080048142A CN 114126643 A CN114126643 A CN 114126643A
- Authority
- CN
- China
- Prior art keywords
- formulation
- lysozyme
- pharmaceutical formulation
- weight
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 70
- 102000016943 Muramidase Human genes 0.000 title claims abstract description 67
- 108010014251 Muramidase Proteins 0.000 title claims abstract description 67
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims abstract description 67
- 239000004325 lysozyme Substances 0.000 title claims abstract description 67
- 229960000274 lysozyme Drugs 0.000 title claims abstract description 67
- 235000010335 lysozyme Nutrition 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims description 71
- 230000000845 anti-microbial effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 238000009472 formulation Methods 0.000 claims abstract description 82
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 29
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 208000036142 Viral infection Diseases 0.000 claims abstract description 17
- 230000009385 viral infection Effects 0.000 claims abstract description 17
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 7
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 46
- 239000002738 chelating agent Substances 0.000 claims description 33
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 20
- 238000001356 surgical procedure Methods 0.000 claims description 20
- 230000003139 buffering effect Effects 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 12
- 239000011787 zinc oxide Substances 0.000 claims description 10
- 229960005336 magnesium citrate Drugs 0.000 claims description 8
- 239000004337 magnesium citrate Substances 0.000 claims description 8
- 235000002538 magnesium citrate Nutrition 0.000 claims description 8
- 239000006199 nebulizer Substances 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 8
- 239000007910 chewable tablet Substances 0.000 claims description 6
- 229940068682 chewable tablet Drugs 0.000 claims description 6
- 241001678559 COVID-19 virus Species 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 26
- 241000894006 Bacteria Species 0.000 abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000000241 respiratory effect Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 230000009291 secondary effect Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 description 38
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 33
- 229960003260 chlorhexidine Drugs 0.000 description 33
- 239000000843 powder Substances 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 13
- 208000034158 bleeding Diseases 0.000 description 13
- 230000000740 bleeding effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000007565 gingivitis Diseases 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 230000002980 postoperative effect Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 238000000889 atomisation Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000003086 colorant Substances 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 241000193403 Clostridium Species 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- 229940051866 mouthwash Drugs 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000004053 dental implant Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010006326 Breath odour Diseases 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000011953 bioanalysis Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000014860 sensory perception of taste Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000605894 Porphyromonas Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035923 taste sensation Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000186524 Clostridium subterminale Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241001468125 Exiguobacterium Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241000563924 Mitu Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000165031 Pseudomonas lactis Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000605036 Selenomonas Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229940045373 chlorhexidine mouthwash Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853215P | 2019-05-28 | 2019-05-28 | |
| US62/853,215 | 2019-05-28 | ||
| PCT/IB2020/055083 WO2020240472A1 (en) | 2019-05-28 | 2020-05-28 | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114126643A true CN114126643A (zh) | 2022-03-01 |
Family
ID=73551002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080048142.9A Pending CN114126643A (zh) | 2019-05-28 | 2020-05-28 | 包含溶菌酶的广谱抗菌药物制剂及其使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200376094A1 (https=) |
| EP (1) | EP3976093A4 (https=) |
| JP (3) | JP7768769B2 (https=) |
| CN (1) | CN114126643A (https=) |
| AR (1) | AR119031A1 (https=) |
| BR (1) | BR112021024001A2 (https=) |
| CA (1) | CA3145530A1 (https=) |
| CO (1) | CO2021017958A2 (https=) |
| IL (1) | IL288531A (https=) |
| MX (1) | MX2021014634A (https=) |
| TW (1) | TW202110474A (https=) |
| WO (1) | WO2020240472A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3928785B1 (en) * | 2020-04-27 | 2024-07-31 | Guangzhou Century Clinical Research Co., Ltd | Medicament and food for use in preventing or treating novel coronavirus pneumonia covid-19 |
| EP4144363A4 (en) * | 2020-04-27 | 2024-05-29 | Guangzhou Century Clinical Research Co., Ltd | Drug, food and application of anti-coronavirus infection |
| WO2023133412A2 (en) * | 2022-01-05 | 2023-07-13 | Prophase Labs, Inc. | Compositions having synergistic anti-viral action and methods for treating coronavirus |
| CN114503981A (zh) * | 2022-01-07 | 2022-05-17 | 上海膜益信息科技有限公司 | 一种不分层防霉液及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
| CA2561876C (en) * | 2004-04-08 | 2013-01-08 | Kenneth Vincent Mason | Antimicrobial compositions and methods for their use |
| CN1583170A (zh) * | 2004-06-10 | 2005-02-23 | 安米 | 用于抗病毒抗耐药菌的人溶菌酶药物及其制法 |
| US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| WO2009051838A1 (en) * | 2007-10-19 | 2009-04-23 | Becton Dickinson And Company | Methods and compositions for the detection of beta-lactamases |
| EP2349209A2 (en) * | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
| CA2905788C (en) * | 2013-03-12 | 2022-08-16 | Emily A. Stein | Dental composition comprising chelator and base |
| CN110352237B (zh) * | 2017-02-28 | 2023-01-10 | 精密生物集团有限公司 | 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌 |
| EP3655020A4 (en) * | 2017-07-17 | 2021-04-07 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Antibacterial methods and related kits |
-
2020
- 2020-05-28 EP EP20815355.1A patent/EP3976093A4/en not_active Withdrawn
- 2020-05-28 BR BR112021024001A patent/BR112021024001A2/pt unknown
- 2020-05-28 MX MX2021014634A patent/MX2021014634A/es unknown
- 2020-05-28 JP JP2021571513A patent/JP7768769B2/ja active Active
- 2020-05-28 AR ARP200101510A patent/AR119031A1/es unknown
- 2020-05-28 WO PCT/IB2020/055083 patent/WO2020240472A1/en not_active Ceased
- 2020-05-28 US US16/885,537 patent/US20200376094A1/en not_active Abandoned
- 2020-05-28 CN CN202080048142.9A patent/CN114126643A/zh active Pending
- 2020-05-28 CA CA3145530A patent/CA3145530A1/en active Pending
- 2020-05-28 TW TW109117916A patent/TW202110474A/zh unknown
-
2021
- 2021-11-29 IL IL288531A patent/IL288531A/en unknown
- 2021-12-28 CO CONC2021/0017958A patent/CO2021017958A2/es unknown
-
2022
- 2022-07-28 US US17/875,872 patent/US20220362354A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,472 patent/US20240066105A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215483A patent/JP2025038034A/ja active Pending
-
2025
- 2025-10-30 JP JP2025183379A patent/JP2026021451A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| KO KY等: "Ethylenediaminetetraacetate and lysozyme improves antimicrobial activities of ovotransferrin against Escherichia coli O157:H7", POULT SCI, pages 406 - 414 * |
| 赵电波等: "天然生物防腐剂溶菌酶的改性研究进展", 中国食品添加剂, no. 05, pages 200 - 204 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3145530A1 (en) | 2020-12-03 |
| CO2021017958A2 (es) | 2022-01-17 |
| JP2022534776A (ja) | 2022-08-03 |
| JP7768769B2 (ja) | 2025-11-12 |
| AR119031A1 (es) | 2021-11-17 |
| IL288531A (en) | 2022-01-01 |
| WO2020240472A1 (en) | 2020-12-03 |
| US20240066105A1 (en) | 2024-02-29 |
| US20220362354A1 (en) | 2022-11-17 |
| US20200376094A1 (en) | 2020-12-03 |
| EP3976093A1 (en) | 2022-04-06 |
| EP3976093A4 (en) | 2023-07-05 |
| TW202110474A (zh) | 2021-03-16 |
| BR112021024001A2 (pt) | 2022-01-25 |
| JP2026021451A (ja) | 2026-02-10 |
| JP2025038034A (ja) | 2025-03-18 |
| MX2021014634A (es) | 2022-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240066105A1 (en) | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same | |
| Cegolon et al. | Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents | |
| US20090252708A1 (en) | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof | |
| CA2982943C (en) | Compositions and methods for treating bacterial infection | |
| JP2014501287A (ja) | 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物 | |
| Elkin et al. | Pseudomonal infection in cystic fibrosis: the battle continues | |
| US20200352986A1 (en) | Methods and compositions for alleviating respiratory dysfunction | |
| UA126993C2 (uk) | Композиція для ерадикації helicobacter pylori | |
| WO2014126594A1 (en) | Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione | |
| Kaur et al. | Dental Caries: A review on etiology, therapeutic approaches, novel formulations, and marketed preparations | |
| Nickles et al. | Evaluation of two siblings with Papillon‐Lefèvre syndrome 5 years after treatment of periodontitis in primary and mixed dentition | |
| EP4076396A2 (en) | Solution and method for reducing the virulence of microbes | |
| RU2762506C1 (ru) | Средство для аппликации полости рта и носа и способ его применения в составе комплексной терапии инфекционно-воспалительных заболеваний носовой и ротовой полости | |
| JP2004529095A (ja) | 抗菌性ｉｂ−３６７ペプチドの経口投与による人工呼吸器関連性肺炎の予防法 | |
| JP7854397B2 (ja) | 微生物感染治療のためのプロテアーゼ製剤 | |
| RU2526121C1 (ru) | Способ лечения больных туберкулезом легких с сопутствующими неспецифическими бронхитами | |
| JPH0327313A (ja) | 生理的用量のビタミンａと治療活性のある各種有効成分とを有する組成物 | |
| Sriudom et al. | Comparison of gargling and swabbing methods for delivering pre-procedural povidone-iodine mouthrinse: a randomised crossover trial | |
| JP4949224B2 (ja) | 薬物除去剤及び薬物除去促進剤 | |
| Dilworth | Antifungal: Oral and oesophogeal candidiasis | |
| EA052469B1 (ru) | Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов | |
| WO2021204861A1 (en) | Compositions for use in the inhibition of coronavirus replication | |
| ALSOFYANI et al. | Use of Oral Antiseptics and its Association with Cardiovascular Events | |
| EA044553B1 (ru) | Средство для аппликации полости рта и носа и способ его применения в составе комплексной терапии инфекционно-воспалительных заболеваний носовой и ротовой полости | |
| JPS61289037A (ja) | 新規去痰薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220301 |
|
| WD01 | Invention patent application deemed withdrawn after publication |